细胞程序性死亡蛋白1配体1(PDL1)重组蛋白
Recombinant Programmed Cell Death Protein 1 Ligand 1 (PDL1)
CD274; PDCD1LG1; B7-H; B7H1; PD-L1; PDCD1L1; PDCD1-LG1; Programed Death Ligand 1
- 编号RPA788Mu01
- 物种Mus musculus (Mouse，小鼠)相同的名称，不同的物种。
- 来源原核表达
- 宿主E.coli
- 内毒素水平<1.0EU/µg(LAL法测定)
- 亚细胞定位细胞膜
- 预测分子量31.2kDa
- 实际分子量38kDa(差异分析请参阅说明书)
- 片段与标签Leu48~Thr290 with N-terminal His Tag
- 缓冲液成份PBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
- 性状冻干粉
- 纯度> 80%
- 等电点6.4
- 应用Positive Control; Immunogen; SDS-PAGE; WB.
如果需要有生物活性的蛋白，请参见活性蛋白。 - 下载英文说明书 中文说明书
- 规格10µg50µg200µg1mg5mg
- 价格¥ 1080¥ 2700¥ 5400¥ 16200¥ 40500
- 欲了解实际交易价格和更多情况，请与当地经销商联系!
序列
用法
Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
储存
避免反复冻融。2-8°C不超过一个月，-80°C不超过12个月。
稳定性
热稳定性以损失率显示。损失率是由加速降解试验决定，具体方法如下：在37°C孵育48小时，没有显著的降解或者沉淀产生。保质期内，在适当的条件下存储，损失率低于5%。
增值服务
相关产品
| 编号 | 适用物种：Mus musculus (Mouse，小鼠) | 应用(仅供研究使用，不用于临床诊断！) |
| RPA788Mu01 | 细胞程序性死亡蛋白1配体1(PDL1)重组蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPA788Mu02 | 细胞程序性死亡蛋白1配体1(PDL1)重组蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAA788Mu01 | 细胞程序性死亡蛋白1配体1(PDL1)多克隆抗体 | WB; IHC; ICC; IP. |
| PAA788Mu02 | 细胞程序性死亡蛋白1配体1(PDL1)多克隆抗体 | WB |
| SEA788Mu | 细胞程序性死亡蛋白1配体1(PDL1)检测试剂盒(酶联免疫吸附试验法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| AEA788Mu | 抗细胞程序性死亡蛋白1配体1抗体(Anti-PDL1)检测试剂盒(酶联免疫吸附试验法) | Enzyme-linked immunosorbent assay for Antibody Detection. |
| LMA788Mu | 细胞程序性死亡蛋白1配体1(PDL1)等多因子检测试剂盒(流式荧光发光法) | FLIA Kit for Antigen Detection. |
参考文献
| 杂志 | 参考文献 |
| Chinese Journal of Cancer | Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications[NCBI: PMC3937742] |
| Leukemia.? | High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial.[Pubmed:24732592] |
| Diabetes?Metab Res Rev. | PD‐L1 gene polymorphisms and low serum level of PD‐L1 protein are associated to type 1 diabetes in Chile[Pubmed:24816853] |
| Lancet Haematol | Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study[PubMed: 26686046] |
| Eur J Cancer. | High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis.[Pubmed:27039170] |
| Journal of Cancer Research and Clinical Oncology | Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer[article:10.1007] |
| Journal of Hematology & Oncology | PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma[pubmed:27737703] |
| Lung Cancer. | High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer.[pubmed:28212990] |
| Oncotarget | Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predictssurvival in advanced biliary tract cancer patients treated with palliative chemotherapy.[pubmed:27780932] |
| Oncotarget | High post-treatment serum levels of soluble programmed cell death ligand 1 predict earlyrelapse and poor prognosis in extranodal NK/T cell lymphoma patients.[pubmed:27105512] |
| Oncotarget. | Soluble PD-L1: A biomarker to predict progression of autologous transplantation in patients with multiple myeloma[pubmed:27566569] |
| Cancer Immunol Immunother. | Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy.[pubmed:28349165] |
| Leukemia | Soluble programmed death-ligand 1 as a prognostic biomarker for overall survival in patients with diffuse large B-cell lymphoma: a replication study and combined analysis of 508 patients[leu2016385a] |
| Medicine | Plasma levels of soluble programmed death ligand-1 may be associated with overall survival in nonsmall cell lung cancer patients receiving thoracic radiotherapy.[pubmed:28207525] |
| Allergology International | Inverse correlation of soluble programmed cell death-1 ligand-1 (sPD-L1) with eosinophil count and clinical severity in allergic rhinitis patients[pubmed:27617656] |
| Medicine | Plasma levels of soluble programmed death ligand-1 may be associated with overall survival in nonsmall cell lung cancer patients receiving thoracic radiotherapy[PMC5319514] |
| American Journal of Respiratory and Critical Care Medicine | Soluble Programed Death Receptor 1 Ligand (sPD-L1) in Pleural Fluid of Patients with Malignant Pleural Mesothelioma (MPM)[Pdf:10.1164] |
| Clinical Lung Cancer | Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non–Small-cell Lung Cancer[Pubmed:29859759] |
| Journal of Rheumatology | Increased levels of soluble programmed death ligand 1 associate with malignancy in patients with dermatomyositis[Pubmed:29419471] |
| Translational Oncology | High Serum Level of Soluble Programmed Death Ligand 1 is Associated With a Poor Prognosis in Hodgkin Lymphoma[Pubmed:29698935] |
| Immunology Letters | Increased levels of soluble co-stimulatory molecule PD-L1 (B7-H1) in the plasma of viraemic HIV-1+ individuals[Pubmed: 30236481] |
| Journal of Cancer Research and Clinical Oncology | Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma[Pubmed: 30267213] |
| Annals of Surgical Oncology | Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between …[Pubmed: 30565045] |
| American Journal of Reproductive Immunology | Identification of programmed cell death 1 and its ligand in the testicular tissue of mice[Pubmed: 30578744] |
| PLoS One | Clinical significance of soluble programmed cell death-1 and soluble programmed cell death-ligand 1 in patients with locally advanced rectal cancer treated …[Pubmed: 30807610] |
| Endocrine Connections | Elevated levels of soluble PD-L1 are associated with reduced recurrence in papillary thyroid cancer[Pubmed: 31252406] |
| Scientific Reports | Prognostic implications of soluble programmed death-ligand 1 and its dynamics during chemotherapy in unresectable pancreatic cancer[Pubmed: 31366979] |
| Critical Reviews in Oncology / Hematology | The Clinical Significance of Soluble PD-1 and PD-L1 in Lung Cancer[Pubmed: 31675543] |
| PLoS One | Clinical implications of APOBEC3A and 3B expression in patients with breast cancer[Pubmed: 32176735] |
| Cancers | Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study[Pubmed: 32085544] |
| Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma[Pubmed: 32054467] | |
| LIVER INTERNATIONAL | The prognostic role of soluble transforming growth factor‐β and its correlation with soluble programmed death‐ligand 1 in biliary tract cancer[Pubmed: 32780918] |
| CANCER IMMUNOLOGY IMMUNOTHERAPY | Prognostic impacts of tumoral expression and serum levels of PD-L1 and CTLA-4 in colorectal cancer patients[Pubmed: 32577816] |
| Soluble PD-L1: a potential immune marker for HIV-1 infection and virological failure[Pubmed: 32443313] | |
| Cancer Immunol Immunother | The clinical implication of soluble PD-L1 (sPD-L1) in patients with breast cancer and its biological function in regulating the function of T lymphocyte[33688997] |
| Acta Biochim Biophys Sin | Prognostic prospect of soluble programmed cell death ligand-1 (sPD-L1) in cancer management[34180502] |
| EMBO J | Microglial PD‐1 stimulation by astrocytic PD‐L1 suppresses neuroinflammation and Alzheimer's disease pathology[34825707] |
| Mol Pharm | A Novel Small Cyclic Peptide-Based 68Ga-Radiotracer for Positron Emission Tomography Imaging of PD-L1 Expression in Tumors[34910492] |
| Mol Hum Reprod | Macrophage Associated Immune Checkpoint CD47 Blocking Ameliorates Endometriosis[Pubmed:35404426] |
| Journal of Nanobiotechnology | Microbial hydrogen “manufactory” for enhanced gas therapy and self-activated immunotherapy via reduced immune escape[Pubmed:35705974] |
| Medicina | Assessment of the RANTES Level Correlation and Selected Inflammatory and Pro-Angiogenic Molecules Evaluation of Their Influence on CRC Clinical Features: A …[Pubmed:35208526] |